Barbora Dybvik - Academia.edu (original) (raw)

Uploads

Papers by Barbora Dybvik

Immunohematology, 2021

The red blood cell (RBC) antigen Wra is a low-prevalence antigen first described in 1953 by Holma... more The red blood cell (RBC) antigen Wra is a low-prevalence antigen first described in 1953 by Holman and assigned to the Diego system in 1995. Because of its low prevalence, Wra is usually absent on commercial screening RBCs and antibody identification panels. When Wr(a+) screening RBCs are available, the corresponding antibody, anti-Wra, is often found in sera from healthy individuals, patients, and pregnant women. Anti-Wra can cause both hemolytic transfusion reactions and hemolytic disease of the fetus and newborn. We describe a fatal acute hemolytic transfusion reaction caused by anti-Wra in a patient with no other RBC alloantibodies. Serologic investigation showed that one of the RBC units the patient received was Wr(a+). Immunohematology 2021;37:20–24.

Fetal Diagnosis and Therapy

Introduction: Targeted routine antenatal prophylaxis with anti-D immunoglobulin (Ig) only to RhD-... more Introduction: Targeted routine antenatal prophylaxis with anti-D immunoglobulin (Ig) only to RhD-negative pregnant women who carry RhD-positive fetuses (determined by fetal RHD genotyping) has reduced D-alloimmunization significantly when administered in addition to postnatal prophylaxis. Achieving high analysis sensitivity and few false-negative fetal RHD results will make RhD typing of the newborn redundant. Postnatal prophylaxis can then be given based on the result of fetal RHD genotyping. Terminating routine RhD typing of the newborns in cord blood will streamline maternity care. Accordingly, we compared the results of fetal RHD genotyping with RhD typing of the newborns. Methods: Fetal RHD genotyping was performed, and antenatal anti-D Ig was administered at gestational week 24 and 28, respectively. Data for 2017–2020 are reported. Results: Ten laboratories reported 18,536 fetal RHD genotypings, and 16,378 RhD typing results of newborns. We found 46 false-positive (0.28%) and ...

Tidsskrift for Den norske legeforening

Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis, 2019

Blood component therapy is considered the gold standard for the treatment of the massively bleedi... more Blood component therapy is considered the gold standard for the treatment of the massively bleeding patient, but it can be challenging to perform outside the hospital environment. The successful experience from the military shows that whole blood can efficiently provide treatment for massively bleeding patients. Whole blood transfusion has been in use in Norway to some extent in paediatric cardiac surgery, but no major interest has been paid from the blood centres to implement the use of whole blood as an alternative or a supplement to traditional blood component therapy. On the other hand, the increasing number of reports showing a potential benefit of whole blood and the availability of the last generation whole blood leukocyte filters, allowing the platelets to remain in the blood product, has led to the first experiences with prehospital use of whole blood in Norway. Our institution is completing the planning of a program for the use of prehospital whole blood transfusion in the...

To reduce the risk of RhD alloimmunization during the last trimester of pregnancy, a targeted rou... more To reduce the risk of RhD alloimmunization during the last trimester of pregnancy, a targeted routine antenatal anti‐D prophylaxis (RAADP) programme was implemented in Norway in 2016. Here, we present and discuss our experience with the nationwide implementation of the programme, and report sample uptake and preliminary data of de novo anti‐D in pregnancy.

Transfusion Medicine